



PHARMA MONTHLY

SEPTEMBER 2026

PROGRESSIVE[®]
Your Progress Our Priority...

www.progressiveshares.com | [f](#) [x](#) [@](#)progressiveshar | [🔍](#) Research Analyst

Equities | Derivatives | Commodities | Currency | PMS | Depository | Mutual Funds | NBFC | e-Broking



Key News for the Month

Company

- Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says
- RPG Life Sciences subsidiary acquires Raghava Life Sciences' API biz for Rs135cr
- Cohance Lifesciences to invest USD18mn in NJ Bio, Aruka Bio
- Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
- FDA cancels drug licenses for Cipla Pharma and Life Sciences Pune carry and forwarding unit
- Lupin gets USFDA approval for Modafinil tablets to treat excessive sleepiness
- Novartis India to pursue therapy-aligned acquisitions; eyes expansion in tier 2 and 3 markets
- Novartis India to acquire Pfizer's 'Minipress' trademark for Rs1,250cr
- Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drug
- Sun Pharma incorporates global treasury arm at IFSC, GIFT City
- Alembic Pharma clears USFDA inspection at Vadodara bioequivalence facility with NIL observations
- AstraZeneca's breast cancer drug fails in late-stage trial
- Dr. Reddy's launches nivolumab biosimilar in India
- Advent inks pact with Yatharth Hospital to invest Rs3,150cr for 24.9% stake
- Dr. Reddy's inks pact with Gilead for once-yearly HIV prevention drug lenacapavir
- QDENGGA dengue vaccine to hit India market in 2027; Dr Reddy's to sell it
- Shilpa Medicare Hyderabad plant inspection concludes with one process remark
- Pfizer India removes products from Karnataka markets after spurious drugs crackdown
- Entod Pharmaceuticals secures patent for its insulin eye drop
- Dr Lal Path Labs to acquire 70% stake in Gujarat-based SN Genelab for Rs168cr
- Sun Pharma inks pact with LIB Therapeutics to sell LDL-C drug
- Natco Pharma to enhance total investment in eGenesis to USD25mn
- USFDA inspection at Zydus Lifesciences' Ahmedabad facility ends with one observation
- Sun Pharma plans USD1bn rupee debt sale to refinance Organon acquisition loan
- Ontario contributes USD1.7mn investment to advance life sciences innovation at Piramal Pharma's Aurora facility
- Aurobindo's arm, Acrotech Biopharma, launches Adquey in US

Industry

- Monsoon illnesses & flu surge lift drug demand
- Pharma sector must attract more investment in clinical trials, R&D: Piyush Goyal
- Centre may provide 100% funding support for medical testing equipment, says Piyush Goyal
- Ind-Ra pegs Pharma FY27 revenue growth at 10% as domestic demand, CDMOs cushion US decline

Global

- Sandoz bets big on biosimilars, aims to double group sales by 2035
- Novo to pay upto USD2.6bn to China's Hengrui for rights to weight-loss pill
- AstraZeneca files for USFDA approval of HUTCHMED lung cancer drug combination
- Lilly's experimental drug cuts weight by 21% in diabetes trial

Tentative ANDA Approvals

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
Lupin	Apixaban Oral Suspension	1.25mg/mL	Alternative administration option for adult patients requiring anticoagulation therapy	Eliquis (Bristol Myers Squibb)	USD4.4bn

Source: Media Reports and Company Press Releases

Final ANDA Approvals

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
Lupin	Midafinil Tablets	100/200mg	Indicated to improve wakefulness in adult patients with excessive sleepiness	Provigil (Nuvo Pharmaceuticals)	USD70.7mn
Aurobindo	Beclomethasone Dipropionate HFA Inhalation Aerosol	40/80mcg	Indicated for complex respiratory therapies	Qvar (Teva)	USD301mn

Source: Media Reports and Company Press Releases

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
3B BlackBio Dx Ltd	1693	17.1%	50.4%	23.2%
Aarti Drugs Ltd	431	4.3%	34.8%	-11.4%
Aarti Pharmed Labs Ltd	952	12.8%	61.6%	14.9%
Abbott India Ltd	27149	5.0%	4.7%	-7.3%
Acutaas Chemicals Ltd	3279	4.0%	28.2%	148.6%
Advanced Enzyme Technologies Ltd	281	-4.5%	9.9%	-13.7%
Ajanta Pharma Ltd	3617	-0.1%	29.0%	50.3%
Akums Drugs and Pharmaceutical Ltd	818	5.3%	75.6%	84.6%
Alembic Pharmaceuticals Ltd	826	-1.2%	24.8%	-8.2%
Alivus Lifesciences Ltd	1379	-1.8%	41.6%	48.4%
Alkem Laboratories Ltd	5146	-3.9%	-3.0%	-5.1%
Anuh Pharma Ltd	88	6.8%	30.7%	4.6%
Apollo Hospitals Enterprise Ltd	8139	-8.1%	9.6%	9.8%
Artemis Medicare Services Ltd	346	8.9%	68.4%	47.9%
Aster DM Healthcare Ltd	696	-8.0%	3.6%	11.0%
AstraZeneca Pharma India	6189	-11.2%	-20.2%	-32.1%
Aurobindo Pharma Ltd	1667	-1.4%	27.9%	53.8%
Bajaj Healthcare Ltd	326	-2.2%	12.6%	-33.2%
Biocon Ltd	371	-8.4%	2.8%	8.8%
Bliss GVS Pharma Ltd	695	12.8%	222.6%	355.1%
Blue Jet Healthcare Ltd	539	-6.7%	64.6%	-14.5%
Caplin Point Laboratories Ltd	2709	7.6%	79.9%	37.6%
Cipla Ltd	1350	-4.7%	10.4%	-10.1%
Cohance Lifesciences Ltd	444	-2.6%	47.1%	-49.5%
Concord Biotech Ltd	1373	-5.3%	35.2%	-16.7%
Dishman Carbogen Amics Ltd	157	-12.1%	20.7%	-43.2%
Divi's Laboratories Ltd	9282	0.4%	56.1%	63.2%
Dr. Agarwal's Health Care Ltd	480	-6.3%	18.1%	-5.5%
Dr. Lal PathLabs Ltd	1988	2.5%	51.3%	27.7%
Dr. Agarwals Eye Hospital Ltd	5124	-4.0%	9.0%	5.4%

Source: BSE website; All prices are as on 30th Sept, 2026

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
Dr. Reddy's Laboratories Ltd	1236	6.1%	-1.5%	1.0%
Emcure Pharmaceuticals Ltd	1942	4.6%	21.7%	51.7%
Eris Lifesciences Ltd	1190	-8.3%	-8.3%	-25.1%
FDC Ltd	340	1.0%	5.8%	-23.2%
Fermenta Biotech Ltd	550	9.9%	72.3%	76.2%
Fischer Medical Ventures Ltd	34	-5.2%	-17.1%	-69.8%
Fortis Healthcare Ltd	768	-15.4%	-3.3%	-20.8%
Gland Pharma Ltd	2904	0.5%	71.1%	45.7%
GSK Pharmaceuticals Ltd	2768	-9.4%	21.2%	4.2%
Glenmark Pharmaceuticals Ltd	2310	-7.2%	8.3%	18.3%
Global Health Ltd	1365	-7.9%	41.9%	3.9%
GPT Healthcare Ltd	151	-1.3%	31.2%	2.7%
Granules India Ltd	847	2.3%	36.4%	64.2%
Gufic Biosciences Ltd	432	4.0%	57.3%	22.5%
Gujarat Themis Biosyn Ltd	388	-8.2%	70.5%	-2.3%
HealthCare Global Enterprises Ltd	666	-10.0%	26.9%	2.9%
Hester Biosciences Ltd	2174	-3.8%	72.2%	14.9%
Hikal Ltd	218	8.0%	48.1%	-13.5%
Indegene Ltd	590	-3.5%	35.8%	5.1%
Indoco Remedies Ltd	263	8.1%	59.6%	-10.1%
Indraprastha Medical Corp. Ltd	349	-3.9%	-6.1%	-21.6%
Innova Captab Ltd	1158	7.4%	68.5%	35.9%
IOL Chemicals and Pharma Ltd	207	6.9%	184.8%	102.2%
IPCA Laboratories Ltd	1927	-2.4%	20.2%	43.7%
Jagsonpal Pharmaceuticals Ltd	237	-1.6%	28.6%	8.1%
Jubilant Pharmova Sciences Ltd	1029	16.6%	26.0%	-4.6%
Jupiter Life Line Hospitals Ltd	253	-14.3%	-0.4%	-16.9%
KMC Speciality Hospitals Ltd	171	26.4%	117.7%	158.5%
Kopran Ltd	278	27.5%	157.7%	59.7%
Kovai Medical Center & Hospital Ltd	6012	-1.0%	19.7%	-2.0%

Source: BSE website; All prices are as on 30th Sept, 2026

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
KIMS Ltd	748	-0.8%	20.2%	6.9%
Krsnaa Diagnostics Ltd	560	0.9%	7.4%	-26.1%
Kwality Pharmaceuticals Ltd	3636	10.7%	178.3%	295.2%
Laurus Labs Ltd	1982	3.9%	99.8%	135.4%
Laxmi Dental Ltd	192	-1.97%	21.6%	-41.2%
Lincoln Pharmaceuticals Ltd	585	-3.7%	3.7%	9.9%
Lupin Ltd	2042	-6.24%	-11.7%	6.9%
Mankind Pharma Ltd	2505	4.4%	24.9%	2.8%
Marksans Pharma Ltd	322	-0.2%	105.1%	95.2%
Max Healthcare Institute Ltd	930	-8.8%	-3.3%	-16.7%
Metropolis Healthcare Ltd	542	-6.9%	24.9%	5.8%
Morepen Laboratories Ltd	126	17.6%	272.8%	162.9%
Narayana Hrudayalaya Ltd	1793	-6.0%	11.7%	3.4%
Natco Pharma Ltd	827	-1.8%	-15.2%	3.9%
Nectar Lifesciences Ltd	10	-17.1%	11.2%	-28.6%
Neuland Laboratories Ltd	21393	-6.7%	78.1%	46.3%
Novartis India Ltd	1924	23.6%	98.2%	119.8%
Onesource Specialty Pharma Ltd	1525	0.7%	3.6%	-16.8%
Orchid Pharma Ltd	996	3.1%	108.2%	42.2%
Panacea Biotech Ltd	365	-5.6%	23.4%	-10.1%
Pfizer (India) Ltd	3876	-17.3%	-17.9%	-23.0%
Piramal Pharma Ltd	206	-3.8%	51.2%	8.1%
Poly Medicure Ltd	1675	-5.0%	40.7%	-13.9%
Procter & Gamble Health Ltd	5561	-3.5%	15.9%	-11.9%
Rainbow Children's Medicare Ltd	1316	-7.0%	13.1%	-3.0%
RPG Life Sciences Ltd	3036	15.8%	64.1%	36.3%
Sai Life Sciences Ltd	1526	4.6%	57.2%	77.3%
Sanofi Consumer Healthcare India Ltd	3806	-8.0%	-11.4%	-19.4%
Sanofi India Ltd	3059	-2.2%	-4.6%	-34.2%
Sastasundar Ventures Ltd	283	-5.5%	8.2%	-7.2%

Source: BSE website; All prices are as on 30th Sept, 2026

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
Senores Pharmaceuticals Ltd	1384	-3.4%	82.6%	101.4%
Sequent Scientific Ltd	236	-10.6%	28.7%	26.4%
Shalby Ltd	139	-10.2%	9.6%	-47.5%
Shilpa Medicare Ltd	1046	10.1%	199.9%	177.2%
Shree Ganesh Remedies Ltd	686	13.3%	63.3%	33.5%
Sigachi Industries Ltd	29	-11.7%	69.7%	-25.4%
SMS Pharmaceuticals Ltd	478	28.6%	27.5%	94.3%
Solara Active Pharma Sciences Ltd	725	14.6%	70.5%	20.0%
Strides Pharma Science Ltd	1118	9.1%	19.2%	35.5%
SPARC Ltd	197	-1.3%	72.1%	52.5%
Sun Pharmaceutical Industries Ltd	1820	-7.0%	3.57%	14.1%
Supriya Lifescience Ltd	951	18.9%	68.3%	30.5%
Suraksha Diagnostic Ltd	355	5.1%	55.8%	19.1%
Suven Life Sciences Ltd	320	-18.5%	140.9%	57.4%
Snycom Formulations (India) Ltd	25	29.5%	144.9%	56.4%
Syngene International Ltd	365	-9.0%	-6.5%	-41.5%
Tarsons Products Ltd	321	-3.1%	92.4%	5.3%
Themis Medicare Ltd	117	-5.9%	77.5%	-13.2%
Thyrocare Technologies Ltd	534	-11.1%	52.8%	-53.9%
Torrent Pharmaceuticals Ltd	4802	-3.5%	13.8%	33.4%
Unichem Laboratories Ltd	546	-1.8%	86.0%	18.2%
Vijaya Diagnostic Centre Ltd	1436	-5.5%	66.7%	43.8%
Vimta Labs Ltd	603	-6.4%	58.3%	-14.6%
Wanbury Ltd	199	-22.0%	-10.6%	-21.8%
Windlas Biotech Ltd	1097	10.4%	48.7%	21.1%
Wockhardt Ltd	2116	12.3%	79.7%	39.7%
Yatharth Hospital & Trauma Care Services Ltd	1034	3.1%	67.5%	39.0%
Zydus Lifesciences Ltd	1163	0.1%	33.5%	18.5%


Source: BSE website; All prices are as on 30th Sept, 2026

NIFTY PHARMA COMPANIES

Company	Price (Rs)	Mcap (Rs mn)	Change		
			1M	6M	12M
Abbott India Ltd	27149	576906	5.0%	4.7%	-7.3%
Alkem Laboratories Ltd	5146	615281	-3.9%	-3.0%	-5.1%
Aurobindo Pharma Ltd	1667	958867	-1.4%	27.9%	53.8%
Ajanta Pharma Ltd	3617	451948	-0.1%	29.0%	50.3%
Biocon Ltd	371	604617	-8.4%	2.8%	8.8%
Cipla Ltd	1350	1090591	-4.7%	10.4%	-10.1%
Divi's Laboratories Ltd	9282	2464079	0.4%	56.1%	63.2%
Dr. Reddy's Laboratories Ltd	1236	1031659	6.1%	-1.5%	1.0%
Gland Pharma Ltd	2904	479043	0.5%	71.1%	45.7%
Glenmark Pharmaceuticals Ltd	2310	651856	-7.2%	8.3%	18.3%
Ipca Laboratories Ltd	1927	488964	-2.4%	20.2%	43.7%
Laurus Labs Ltd	1982	1070559	3.9%	99.8%	135.4%
Lupin Ltd	2042	933669	-6.2%	-11.7%	6.9%
Piramal Pharma Ltd	206	274657	-3.8%	51.2%	8.1%
Mankind Pharma Ltd	2290	945781	4.4%	24.9%	2.8%
Sun Pharmaceutical Industries Ltd	1820	4366790	-7.0%	3.57%	14.1%
Sai Life Sciences Ltd	1526	323948	4.6%	57.2%	77.3%
Torrent Pharmaceuticals Ltd	4802	1625046	-3.5%	13.8%	33.4%
Wockhardt Ltd	2116	343752	12.3%	79.7%	39.7%
Zydus Lifesciences Ltd	1163	1160446	0.1%	33.5%	18.5%

Source: NSE website, Company Research; All prices are as on 30th Sept, 2026

Nifty Pharma Index Vs. Nifty Index



Source: NSE website

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

· PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

• PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research analyst has served as officer, director or employee of the subject company: NO

· Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai-400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500

Compliance Officer:

Ms. Mamatha Poojari,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500

Grievance Officer:

Email: grievancecell@progressiveshares.com